APPENDICURE

The Question Most Patients Never Think to Ask

If you’re getting ready for surgery, you’re probably focused on the questions everyone asks. Do I trust my surgeon. What will recovery look like. Did they get it all.

Those questions matter. But there’s another one that almost no one brings up before surgery, and it can quietly shape what happens next in your treatment.

THE QUESTION What happens to my tumor after it’s removed?

I did not know to ask this question and David’s tumor was discarded 6 weeks after surgery.

The part most patients are never told

Researchers can take a small piece of a tumor, keep the tissue alive in the lab, and test how it responds to different drugs. It’s called a patient-derived tumor slice, and it’s one of several approaches being developed to make cancer treatment less of a guess.

A study presented at the American Association for Cancer Research annual meeting this year looked at this technique across 40 gastrointestinal cancer specimens, including appendiceal cancer. The researchers, led by a team at UC San Diego, worked out how much natural variation exists between tumor slices so they could tell the difference between a real drug response and normal biological noise. They then showed that a slice’s response to a pan-RAS inhibitor predicted the response seen in matched organoids and xenografts, which are two other laboratory models grown from the same patient’s tumor.

That is a meaningful step. Laboratory models that agree with each other are more trustworthy than any single model on its own. It does not yet prove that these tests will predict what happens inside a patient, but it strengthens the scientific foundation for trying.

Why this rarely happens

When a tumor is removed during surgery, it goes to pathology for diagnosis. Some of the tissue may be stored in a biobank. For most patients, that’s where the story ends.

Very little of what is removed is used to actively test which treatments might work. Not because it couldn’t be. Because the system is not set up to do this routinely, and because it requires coordination that has to happen before the surgery, not after.

The timing problem

This kind of testing requires fresh, living tissue. In most protocols, the tumor has to be processed within hours of being removed. If nothing is arranged in advance, the window closes and the opportunity is gone.

That is the part worth understanding before you walk into the operating room.

One question to add to your list

This is not about piling more pressure onto yourself before surgery. It is about adding one informed question to the ones you are already asking your team.

ASK YOUR TEAM Is there any way my tumor can be used to test which treatments might work, through a research study, a clinical trial, or an institutional program here?

Sometimes the answer is yes and you didn’t know the option existed. Sometimes the answer is no because your center doesn’t offer it. Either way, you will know, and you can ask whether tissue can be preserved for future use.

Why this matters more in appendix cancer

Patients with appendiceal cancer already know the shape of the problem. There are fewer standard treatment options than in more common cancers. Tumors behave very differently from one person to the next. Treatment decisions often feel like educated guesses because the evidence base is thinner.

That is exactly why research into tumor-specific drug testing matters here. Appendiceal cancer is one of the tumor types where broad population averages tell you the least about what will happen to any individual patient. Approaches that work directly with a patient’s own tissue, even in research settings, are moving the field toward better answers.

Where this is going

None of this is standard care today. Patient-derived tumor slices, organoids, and related techniques are still research tools. They are not something you can simply order at most hospitals, and the results are not yet used to direct clinical decisions outside of studies.

But the direction is clear. The science is moving toward a future where treatment decisions are informed by how a specific tumor actually responds, not just by statistics gathered from other patients. Getting there requires that tissue be collected, preserved, and studied, and that requires patients and families knowing to ask.

The bottom line

Before surgery, the question everyone asks is whether the surgeon can get it all.

The question worth adding is whether anything can be done with the tumor itself to help guide what comes next. Whether it gets asked often comes down to one thing. Whether someone thought of it in time.

PRE-SURGERY CHECKLIST

Questions to Ask Before Your Tumor Is Removed

Bring this checklist to your pre-surgical appointments. You do not need to ask every question, but reading through them can help you decide which ones matter for your situation.

Understanding the surgery

☐  What exactly is being removed?☐  When and how will I receive my pathology results?

Tumor preservation

☐  Will any part of my tumor be stored or biobanked?☐  Can a portion be preserved for future research or testing?☐  If I want access to my tissue later, what is the process?

Research and precision medicine options

☐  Does this hospital participate in any programs that test tumor response to drugs, such as organoid or tumor slice studies?☐  Are there clinical trials or research studies here that use fresh tumor tissue?☐  Would my case qualify for any of them?

Timing and coordination

☐  If fresh tissue is needed, has anything been arranged in advance with the surgical and pathology teams?☐  What is the deadline for a decision about tissue use?

Genomic testing

☐  Will my tumor be sent for genomic (next-generation sequencing) testing?☐  Which platform will be used?☐  Will I receive a full copy of the results?

Logistics

☐  What happens to my tumor after pathology is complete?☐  Can tissue be sent to another institution later if needed?☐  What consent forms are involved for research use?

Additional considerations

☐  Should I get a second opinion before surgery?☐  Will my case be reviewed by a tumor board?

SOURCE

Gulay K, Medari R, Ng I, et al. Benchmarking human tumor slices from gastrointestinal malignancies for precision cancer therapy. American Association for Cancer Research Annual Meeting 2026; Abstract LB483. Cancer Res 2026;86(8_Suppl):LB483.

This article is for educational purposes and does not constitute medical advice. Always discuss treatment decisions with your own care team.